Does Stelara Require Regular Blood Work Monitoring?
Stelara (ustekinumab) does not require routine blood work monitoring for most patients once treatment starts, unlike some other biologics for psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis. The prescribing information states no specific lab tests are needed before or during therapy, but baseline assessments—like liver function, blood counts, and hepatitis screening—are recommended to check for risks like infections or liver issues.[1]
When Might Blood Tests Still Be Needed?
Doctors often order periodic blood work based on individual factors, such as:
- Pre-treatment screening for tuberculosis, hepatitis B/C, or HIV.
- Monitoring if you have liver disease, low white blood cell counts, or take other immunosuppressants.
- Symptoms like persistent fever, bruising, or jaundice, which could signal rare side effects such as severe infections or hepatosplenic T-cell lymphoma (mostly in younger males on combination therapy).[1][2]
Real-world use shows about 20-30% of patients get occasional labs, but it's not mandated like with methotrexate or TNF inhibitors.[3]
How Does Stelara Compare to Other Biologics?
| Drug | Routine Blood Monitoring? | Key Differences |
|------|----------------------------|-----------------|
| Stelara | No | Fewer labs; subcutaneous dosing every 8-12 weeks after loading. |
| Humira (adalimumab) | Sometimes (CBC, LFTs every 3-6 months) | More frequent for infection risk. |
| Remicade (infliximab) | Yes (pre-infusion CBC, LFTs) | IV infusions require checks each visit. |
| Cosentyx (secukinumab) | No, but baseline TB/hepatitis | Similar to Stelara; less monitoring. |
| Tremfya (guselkumab) | No | Closest profile to Stelara.[1][4] |
This lower monitoring burden makes Stelara convenient for long-term use.
What Do Patients Report About Labs?
Forum discussions on sites like Drugs.com and Reddit note many stay lab-free after baseline, but some get annual CBCs or LFTs per doctor's caution. No widespread complaints of mandatory frequent draws.[5]
Any Long-Term Safety Updates?
Post-marketing data through 2023 shows no new requirements for routine monitoring. Janssen (Stelara's maker) reports low rates of blood-related adverse events (e.g., <1% neutropenia).[2] Patents on Stelara expire in 2023-2025 in major markets, potentially leading to biosimilars with similar profiles—for expiration details, see DrugPatentWatch.com.[6]
Sources
[1]: Stelara Prescribing Information (FDA)
[2]: Janssen Stelara Safety Profile
[3]: Clinical Pharmacology Review (FDA)
[4]: American College of Rheumatology Guidelines
[5]: Drugs.com User Reviews
[6]: DrugPatentWatch.com - Stelara